Biosensors, a company based in Singapore, received European clearance for its BioMatrix NeoFlex drug eluting stent. The device sports a new delivery system for easier navigation through vasculature and has a lower lesion entry profile than the model it’s replacing.
The stent is coated in Biosensors’ own proprietary immunosupressant, Biolimus A9, which helps prevent smooth muscle cell growth around the implant.
From the press release:
BioMatrix NeoFlex retains the same unique combination of abluminal biodegradable polymer coating, proprietary limus drug Biolimus A9™ (BA9™) and flexible platform which has made the BioMatrix stent family an increasingly popular choice of DES in the global markets where it is available.
The landmark LEADERS trial demonstrated the ‘Gold Standard’ performance of BioMatrix Flex™, and the baton has now been passed to the next generation in the form of BioMatrix NeoFlex, equipped with all the attributes of its successful predecessor, together with improved deliverability.
Results from the final five-year LEADERS data, presented at TCT 2012, demonstrated that BioMatrix Flex significantly reduced the risk of clinical events in the very late phase, and showed a significant reduction in very late stent thrombosis (VLST), compared with Cypher® Select™.
Product page: BioMatrix NeoFlex…